Development of very promising humanized therapeutic mAbs efficiently neutralizing a novel immunosuppressive pathway involved in a wide range of cancers

Project Information

TUMADOR

Grant agreement ID: 602200

Project closed

Start date 1 September 2013

End date 28 February 2018

Funded under

• Specific Programme "Cooperation": Health

Total cost € 7 750 804,44

EU contribution € 5 978 890,00

Coordinated by

CENTRE DE LUTTE CONTRE LE CANCER LEON BERARD
France